Pharmaceutical

Dermavant acquisition expands Organon’s dermatology portfolio

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology portfolio.

Oct 30, 2024 - 04:00
Dermavant acquisition expands Organon’s dermatology portfolio
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology portfolio.
Read the original article

Tags:

Previous Article

Arrivo targets major depressive disorder in females after early efficacy data

Next Article

Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

US FDA approves Novartis’ Fabhalta in IgAN treatment

US FDA approves Novartis’ Fabhalta in IgAN treatment

Aug 9, 2024

Opinion: Gain-of-function research is about much more than dangerous pathogens

Opinion: Gain-of-function research is about much more t...

Jul 22, 2023

How immuno-oncology private equity performed in the pha...

Jul 31, 2023